Christopher P. Mill

The University of Texas MD Anderson Cancer Center

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 13 papers. Top paper: “Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1”.

Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1

Leukemia(2022)10.1038/s41375-022-01707-w

N/A

0.666DataRank · unranked

84 citations

Naval Daver, Steffen Boettcher, Christopher P. Mill, Koji Sasaki, Christine Birdwell +11 more

Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1

Blood Cancer Journal(2023)10.1038/s41408-023-00826-6

N/A

0.604DataRank · unranked

55 citations

Christopher P. Mill, Christine Birdwell, John A. Davis, Kaberi Das, Steffen Boettcher +13 more

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

Blood(2024)10.1182/blood.2023022832

N/A

0.568DataRank · unranked

43 citations

Jessica Piel, Michael P. Collins, Murphy Hentemann, Branko Cuglievan, Christopher P. Mill +21 more

BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma

Leukemia(2021)10.1038/s41375-021-01181-w

N/A

0.510DataRank · unranked

29 citations

Christopher P. Mill, Dimuthu Perera, Christine Birdwell, Qing Deng, Haopeng Yang +13 more

Preclinical efficacy of CDK7 inhibitor–based combinations against myeloproliferative neoplasms transformed to AML

Blood(2024)10.1182/blood.2024026388

N/A

0.395DataRank · unranked

10 citations

Christopher P. Mill, Prithviraj Bose, Lucia Masárová, Naveen Pemmaraju, Andrew Dunbar +18 more

Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression

Leukemia(2023)10.1038/s41375-023-02108-3

N/A

0.373DataRank · unranked

11 citations

Warren Fiskus, Tapan M. Kadia, Christopher P. Mill, Koji Sasaki, Naval Daver +13 more

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1

Leukemia(2023)10.1038/s41375-023-01882-4

N/A

0.360DataRank · unranked

10 citations

Warren Fiskus, Kaberi Das, John A. Davis, Christine Birdwell, Tapan M. Kadia +11 more

Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM)

Blood Cancer Journal(2024)10.1038/s41408-024-00981-4

N/A

0.287DataRank · unranked

4 citations

Warren Fiskus, Courtney D. DiNardo, Patrick K. Reville, John A. Davis, Christine Birdwell +10 more

Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase

Blood Advances(2025)10.1182/bloodadvances.2025016898

N/A

0.262DataRank · unranked

4 citations

Lucia Masárová, Christopher P. Mill, Christine Birdwell, Kaberi Das, Hanxi Hou +16 more

BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML

Leukemia(2025)10.1038/s41375-025-02842-w

N/A

0.165DataRank · unranked

2 citations

Warren Fiskus, Christopher P. Mill, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo +13 more

Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations

Blood Cancer Journal(2025)10.1038/s41408-025-01251-7

N/A

0.104DataRank · unranked

1 citations

Christopher P. Mill, Jessica Piel, Mike Collins, Murphy Hentemann, Branko Cuglievan +18 more

Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1

Blood Neoplasia(2025)10.1016/j.bneo.2025.100145

N/A

0.104DataRank · unranked

1 citations

Wei‐Ying Jen, Guillermo Montalban‐Bravo, Xuemei Wang, Sanam Loghavi, Sravanthi Lavu +15 more

Mechanistic basis and efficacy of targeting the β-catenin–TCF7L2–JMJD6–c-Myc axis to overcome resistance to BET inhibitors

Blood(2020)10.1182/blood.2019002922

N/A

0DataRank · unranked

73 citations

Warren Fiskus, Christopher P. Mill, Dimuthu Perera, Taghi Manshouri, Bernardo H Lara +18 more